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Objective: To estimate preterm birth risk among infants of
HIV-infected women in Lilongwe, Malawi, according to maternal
antiretroviral therapy (ART) status and initiation time under
Option B+.
Design: A retrospective cohort study of HIV-infected women
delivering at $27 weeks of gestation, April 2012 to November
2015. Among women on ART at delivery, we restricted our analysis
to those who initiated ART before 27 weeks of gestation.
Methods: We defined preterm birth as a singleton live birth at $27
and ,37 weeks of gestation, with births at ,32 weeks classified as
extremely to very preterm. We used log-binomial models to estimate
risk ratios and 95% confidence intervals for the association between
ART and preterm birth.
Results: Among 3074 women included in our analyses, 731
preterm deliveries were observed (24%). Overall preterm birth risk
was similar in women who had initiated ART at any point before 27
weeks and those who never initiated ART (risk ratio = 1.14; 95%
confidence interval: 0.84 to 1.55), but risk of extremely to very
preterm birth was 2.33 (1.39 to 3.92) times as great in those who
never initiated ART compared with those who did at any point
before 27 weeks. Among women on ART before delivery, ART
initiation before conception was associated with the lowest preterm
birth risk.
Conclusions: ART during pregnancy was not associated with
preterm birth, and it may in fact be protective against severe adverse
outcomes accompanying extremely to very preterm birth. As
preconception ART initiation appears especially protective,
long-term retention on ART should be a priority to minimize
preterm birth in subsequent pregnancies.
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option B, PMTCT
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INTRODUCTION
Preterm birth, often defined as birth before 37 weeks of
gestation,1 is the second-leading cause of death in children
younger than 5 years,2 and accounts for 75% of all perinatal
mortality worldwide.3,4 Of the estimated 15 million infants
born preterm in 2010, more than 1 million died as a result of
prematurity.1–4 In sub-Saharan Africa, approximately 12% of
live births are preterm, with Malawi registering the highest
preterm birth prevalence worldwide (18%).5
HIV is also endemic in sub-Saharan Africa, with 59%
of all prevalent HIV infections occurring among women.6
Prevention of mother-to-child HIV transmission (PMTCT) is
thus a major public health priority. Antiretroviral therapy
(ART) for HIV-infected women during pregnancy can
virtually eliminate the risk of vertical HIV transmission,7–9
with the additional, important benefit of reduced maternal
morbidity and mortality.10–13
In July 2011, Malawi became the first country to adopt
a strategy of universal lifelong ART for pregnant and
breastfeeding women regardless of HIV disease stage or
CD4 count.14 The scale-up of this approach, called “Option
B+,” is expected to help bring an end to new pediatric HIV
infections and substantially improve maternal health in settings
with high HIV burdens.15 Since the introduction of Option B+
in Malawi, the number of pregnant or breastfeeding women on
ART has increased dramatically,16 and in 2013 the World
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Health Organization recommended it for all countries with
a generalized HIV epidemic.17
Despite the clear benefits of Option B+ for maternal
health and the prevention of vertical HIV transmission, the
effects of ART exposure during pregnancy on fetal develop-
ment and birth outcomes are still unclear.18–24 In particular,
few studies have examined the relationship between the
timing of maternal ART initiation and preterm deliv-
ery.18,25–29 In this study, we used data from the maternity
unit of a large, urban hospital in Malawi to estimate preterm
birth risk among HIV-infected women according to maternal
ART status and time of ART initiation in the Option B+ era.
METHODS
Study Design, Setting, and Population
We conducted a retrospective cohort study using data
collected at delivery from HIV-infected pregnant women for
whom the date of last menstrual period (LMP) was available
and who delivered a singleton live birth at Bwaila Hospital in
Lilongwe, Malawi, from April 1, 2012 through November 15,
2015. Study data were obtained from a point-of-care elec-
tronic medical record system (POC-EMRS) developed by
Baobab Health Trust and hosted at the hospital. All records in
the POC-EMRS were entered directly by a health care worker
at the time of delivery. Information about HIV status and
ART (for HIV-infected women) was cross-checked with
documentation in the mother’s personal health passport,
a government-issued document containing information on
general history, diagnoses, treatments, antenatal consulta-
tions, and deliveries.
ART duration during pregnancy is intrinsically linked
to length of gestation (and thus preterm birth): women
initiating ART later in pregnancy are necessarily closer to
reaching term and are therefore less likely to experience
preterm birth. In an attempt to remove this potentially
confounding relationship from our analysis, we constructed
our study population such that the risk period for the outcome
(preterm birth) was entirely separate from the eligible ART
start times. Specifically, we restricted our analysis to women
who (1) delivered on or after 27 weeks of gestation and (2)
either started ART before 27 weeks or did not receive ART at
all before delivery (Fig. 1). In other words, we chose a cutoff
of 27 weeks to define the start of the risk period for preterm
birth. This start point is at the upper end of values (which
range from 20 to 28 weeks) that have been used in other
settings1; this choice allowed us to minimize the number of
women initiating ART during pregnancy that we would need
to exclude to keep ART start times separate from the preterm
risk period. Women with missing information on the main
exposure (ART use) were also excluded.
This study was approved by the National Health
Sciences Research Committee of Malawi and the Institutional
Review Board at the University of North Carolina, Chapel Hill.
Variable Definitions and Classifications
HIV Status
Each woman’s HIV status was determined on maternity
unit admission. Women whose health passports indicated
prior HIV-positive test results were considered to be HIV-
infected; women without health passport documentation of
HIV-positive status underwent HIV testing. Women found to
be HIV-infected based on either the health passport or testing
at delivery were recorded as such in the database and were
eligible for study inclusion.
Main Outcome—Preterm Birth
Preterm birth status was based on gestational age at
delivery, calculated as the difference between delivery date and
the LMP date recorded in the health passport during the first
antenatal visit. We defined preterm birth as birth on or after 27
weeks and before 37 weeks of gestation. Births occurring at
37+ weeks of gestation were considered full term.1
Main Exposure—ART
ART status and timing of initiation were determined at
delivery according to maternal interview and information
recorded in the health passport. Eligible HIV-infected women
with no history of ART use before delivery comprised the
“never initiated” group in our analysis. Women whose health
passports indicated ART initiation at or after 27 weeks of
gestation (but before delivery) were excluded from the
analysis, as their ART exposure during pregnancy began
after the start of the preterm birth risk period. The remaining
ART-exposed women were assigned to one of 3 categories
according to timing of ART initiation: (1) before pregnancy
(on ART at conception), (2) during the first trimester, or (3)
during the second trimester (specifically, the portion of the
second trimester ,27 weeks).
FIGURE 1. Study eligibility on the 
basis of maternal ART start time and 
gestational age at birth.
Confounders
We used a directed acyclic graph,30,31 an epidemiolog-
ical tool for encoding relationships among variables in studies
of causal effects, to identify potential confounders. This tool
helps to ensure that potential confounders are associated with
both the exposure and the outcome, but are not on the causal
pathway between them. In developing a directed acyclic
graph with variables in our database, we identified mother’s
education, age, and parity as potential confounders for
inclusion in the analysis. Based on the functional form of
the relationship between each confounder and the outcome,
we modeled mother’s age as continuous and parity as ordinal.
We used a manual, backward elimination, change-in-estimate
strategy at a 10% retention threshold to assess the necessity of
including each confounder in the final model.32 We were
unable to assess education as a confounder, as values for this
variable were missing from 95% of records.
Statistical Analyses
We used Fisher exact tests to test differences in
proportions between groups, and t tests and 1-way analysis
of variance to test differences in means as appropriate. We
used log-binomial regression models to estimate unadjusted
and adjusted risk ratios (uRRs and aRRs, respectively) and
95% confidence intervals (CIs) of the association between
ART exposure status and preterm birth (with those who were
on ART as referent), and ART initiation time and preterm
birth (with those initiating before conception as referent).
In subanalyses, we considered 3 preterm birth sub-
categories: extremely to very preterm (27 to ,32 weeks),
moderate preterm (32 to ,34 weeks), and late preterm (34 to
,37 weeks).1 In the first subanalysis, we treated extremely to
very preterm births (versus full term) as the outcome,
excluding moderate to late preterm births. In a second
subanalysis, we treated moderate to late preterm births (again
versus full term) as the outcome, this time excluding
extremely to very preterm births. In a third subanalysis, we
dichotomized the outcome as ,34 weeks versus $34 weeks
(extremely to moderate preterm versus late preterm or full
term), because births before 34 weeks’ gestational age require
advanced neonatal support, and their relationship with ART
status and initiation time is thus of high clinical interest in
this setting.
All statistical analyses were performed using SAS
software, version 9.4 (SAS Institute Inc., Cary, NC).
RESULTS
Among 66,029 women who delivered in the maternity
ward at Bwaila Hospital during the study period, 6853
women (10.4%) were known to be HIV-infected (Fig. 2).
Of these, 1733 (25.2%) were excluded because of missing
LMP, 66 (1.0%) because of delivery before 27 weeks, and 66
(1.0%) because of multiple gestations. Among the women
who were excluded for having delivered before 27 weeks, 17
had missing ART initiation time, 22 started ART before
conception, 21 started ART during pregnancy, and 6 were not
on ART, including 1 stillbirth. The remaining 4988 HIV-
infected women (72.8%) had singleton live births at 27+
weeks of gestation and thus had eligible outcomes. After
excluding 1264 women (25.3%) with missing ART initiation
time and 650 (13.0%) who initiated ART at or after 27 weeks,
3074 women were included in the analyses. Compared with
the 3724 women who had ART initiation time available,
women who were excluded because of missing ART
initiation time were on average slightly older and had similar
parity, but a slightly lower percentage of preterm infants
(19.4% versus 22.1%, see Table 1, Supplemental Digital Content,
FIGURE 2. Flow diagram of the
inclusion criteria for the women
included in the analysis.
http://links.lww.com/QAI/A953). Among included women, most
had initiated ART before pregnancy (N = 1139, 37.0%) or during
the second trimester (N = 1503, 48.9%). Only 5.4% had not
initiated ART before delivery (N = 165).
On average, women who did not start ART before
delivery were younger than those who had received ART
during pregnancy, and age at delivery increased with earlier
ART initiation times (P , 0.001) (Table 1). The distribution
of parity was different across the ART exposure categories
(P , 0.001), and mean gestational age at delivery was
similar between those who never initiated ART and those
who were on ART, regardless of ART initiation time (P =
0.05). A total of 731 preterm births were observed during the
study period (risk = 24%; 95% CI: 22% to 25%), with 149
being extremely to very preterm, 94 moderate preterm, and
488 late preterm. Women who delivered preterm babies
were on average younger than those who delivered full term
babies (mean age = 27.6 versus 28.4, P , 0.001).
Overall, preterm birth risk was similar in women who
never initiated ART compared with those who had initiated
ART at any point before delivery (24.8% versus 23.7%;
aRR = 1.14; 95% CI: 0.84 to 1.55) (Table 2). Among women
who initiated ART before delivery, preterm risk was lowest in
those starting ART before conception, with aRRs for those
initiating during the first and second trimester of 1.31 (95%
CI: 1.03 to 1.68) and 1.17 (0.99 to 1.37), respectively.
Preterm risk was also elevated in those never initiating ART
versus those starting ART before pregnancy (aRR = 1.27;
95% CI: 0.92 to 1.76).
In subanalyses, we found a strong association between
no ART use during pregnancy and extremely to very preterm
birth versus full term birth (aRR = 2.33; 95% CI: 1.39 to 3.92)
(Table 3). Among women who started ART before delivery,
risk of extremely to very preterm birth was elevated in those
starting ART in the first trimester (aRR = 1.30; 95% CI: 0.72
to 2.36) but not the second trimester (aRR = 1.00; 95% CI:
0.68 to 1.48) compared with women starting before concep-
tion. Not starting ART before delivery more than doubled the
risk of extremely to very preterm birth compared with starting
ART before pregnancy (aRR = 2.41; 95% CI: 1.36 to 4.24).
Risk of moderate to late preterm (versus full term) birth
was similar in those not initiating ART before delivery and
those who were on ART (aRR = 0.86; 95% CI: 0.55 to 1.34)
(Table 3), but among those on ART at delivery, initiation in
either the first trimester or second trimester was associated
with a higher risk of moderate to late preterm birth compared
with ART initiation before conception.
Finally, we found suggestion that not starting ART
before delivery increased risk of birth at less than 34 weeks’
gestation, although the estimate was imprecise (aRR = 1.42;
95% CI: 0.85 to 2.36) (Table 3). Among those initiating ART
before delivery, risk of birth before 34 weeks was similar
among those starting ART before pregnancy and those
starting during the second trimester, but the point estimate
for ART initiation during the first trimester suggested
increased risk. The point estimate comparing no ART to
ART initiated before pregnancy also suggested increased risk,
but this estimate was similarly imprecise.
DISCUSSION
In this study of infants born to HIV-infected mothers in
Malawi since the start of Option B+, we did not find a strong
association between ART initiation before delivery and
preterm birth overall. Importantly, we found ART to be quite
strongly associated with a reduced risk of extremely to very
preterm birth (birth between 27 and 32 weeks of gestation),
and moderately associated with a reduction in preterm birth
before 34 weeks. These results are encouraging because
mortality increases as gestational age decreases, with only
30% of babies born between 28 and 32 weeks in low-income
countries surviving.1 In general, ART initiation before
conception was associated with better outcomes relative to
ART nonuse, particularly with respect to the more severe
preterm birth outcomes. Among women who were on ART
before delivery, initiation before conception or during the
second trimester was associated with lower risk of the more
severe preterm birth outcomes than was initiation during the
first trimester.
Our findings related to early ART initiation and overall
preterm birth risk are consistent with previous studies that
have shown a protective effect of earlier maternal ART
against preterm birth. A study of predominantly black African
pregnant women delivering at a single hospital in London
found a decreased odds of preterm delivery among women
who conceived while receiving ART compared with women
TABLE 1. Characteristics of Study Population
Characteristics













Mother’s age, mean (SD) 27.6 (5.6) 28.4 (5.8) 30.4 (5.4) 27.2 (5.4) 26.9 (5.5) 25.6 (5.5)
Gestation weeks at delivery, mean (SD) 34.0 (2.2) 39.4 (1.3) 38.3 (2.7) 37.9 (2.9) 38.1 (2.8) 38.0 (3.3)
Parity, N (%)
Nulliparity 20 (3.3) 46 (2.3) 12 (1.1) 9 (4.1) 40 (3.4) 5 (4.1)
Primiparity (1 child) 163 (26.9) 567 (28.6) 239 (22.3) 64 (29.2) 384 (32.7) 43 (35.5)
Low multiparity (2–4 children) 394 (65.0) 1243 (62.8) 739 (68.9) 140 (63.9) 695 (59.2) 63 (52.1)
Grand multiparity ($5 children) 29 (4.8) 124 (6.3) 82 (7.7) 6 (2.7) 55 (6.7) 10 (8.3)
*Before 27 weeks.
who received ART after conception.27 Results from a study in
Malawi and Mozambique showed a protective effect of
a longer course of ART during pregnancy against preterm
birth, although the investigators did not differentiate between
those starting ART before conception and those starting
during pregnancy.28
Other studies have found ART initiation before
pregnancy to be associated with increased preterm birth
TABLE 2. Associations Between ART Status and Timing of Initiation With Preterm Birth
Preterm (N = 731), N (%) Full Term (N = 2343), N (%) Unadjusted RR (95% CI) Adjusted RR* (95% CI)
ART initiation status
On ART 690 (94.4) 2219 (94.7) 1.00 1.00
Never initiated 41 (5.6) 124 (5.3) 1.05 (0.80 to 1.38) 1.14 (0.84 to 1.55)
ART initiation time
Before pregnancy 235 (32.2) 904 (38.6) 1.00 1.00
1st trimester 77 (10.5) 190 (8.1) 1.40 (1.12 to 1.74) 1.31 (1.03 to 1.68)
2nd trimester† 378 (51.7) 1125 (48.0) 1.22 (1.06 to 1.41) 1.17 (0.99 to 1.37)
Never initiated 41 (5.6) 124 (5.3) 1.20 (0.90 to 1.61) 1.27 (0.92 to 1.76)
*Adjusted for mother’s age and parity.
†Before 27 weeks.
TABLE 3. Associations Between ART Status and Timing of Initiation With Alternate Preterm Categorizations
Extremely to Very Preterm*
(N = 149), N (%)
Full Term†






On ART 133 (86.3) 2219 (94.7) 1.00 1.00
Never initiated 16 (10.7) 124 (5.3) 2.02 (1.24 to 3.30) 2.33 (1.39 to 3.92)
ART initiation time
Before pregnancy 50 (33.6) 904 (38.6) 1.00 1.00
1st trimester 14 (9.4) 190 (8.1) 1.31 (0.74 to 2.32) 1.30 (0.72 to 2.36)
2nd trimester§ 69 (46.3) 1125 (48.0) 1.10 (0.77 to 1.57) 1.00 (0.68 to 1.48)
Never initiated 16 (10.7) 124 (5.3) 2.18 (1.28 to 3.75) 2.41 (1.36 to 4.24)
Moderate to Late Pretermk
(N = 582), N (%)
Full Term†






On ART 557 (95.7) 2219 (94.7) 1.00 1.00
Never initiated 25 (4.3) 124 (5.3) 0.84 (0.58 to 1.20) 0.86 (0.55 to 1.34)
ART initiation time
Before pregnancy 185 (31.8) 904 (38.6) 1.00 1.00
1st trimester 63 (10.8) 190 (8.1) 1.47 (1.14 to 1.88) 1.36 (1.02 to 1.82)
2nd trimester§ 309 (53.1) 1125 (48.0) 1.27 (1.08 to 1.49) 1.23 (1.02 to 1.48)
Never initiated 25 (4.3) 124 (5.3) 0.99 (0.68 to 1.45) 0.99 (0.63 to 1.57)
,34 wk (N = 243), N (%) ‡34 wk (N = 2831), N (%) Unadjusted RR (95% CI) Adjusted RR‡ (95% CI)
ART initiation status
On ART 227 (93.4) 2682 (94.7) 1.00 1.00
Never initiated 16 (6.6) 149 (5.3) 1.24 (0.77 to 2.01) 1.42 (0.85 to 2.36)
ART initiation time
Before pregnancy 83 (34.2) 1056 (37.3) 1.00 1.00
1st trimester 24 (9.8) 243 (8.6) 1.23 (0.80 to 1.90) 1.24 (0.79 to 1.96)
2nd trimester§ 120 (49.4) 1383 (48.9) 1.10 (0.84 to 1.43) 1.02 (0.76 to 1.37)
Never initiated 16 (6.6) 149 (5.3) 1.33 (0.80 to 2.22) 1.47 (0.86 to 2.52)
*Extremely to very preterm: 27 to ,32 gestation weeks.
†Full term: $37 gestation weeks.
‡Adjusted for mother’s age and parity.
§Before 27 weeks.
kModerate to late preterm: 32 to ,37 gestation weeks.
risk. In an analysis of abstracted obstetrical records at 6 sites 
in Botswana, women starting highly active ART (HAART) 
before pregnancy had a higher odds of preterm delivery 
compared with HIV-infected women with no ART exposure 
and those initiating HAART or zidovudine monotherapy 
during pregnancy.20 Similarly, results from a prospective 
cohort study in Brazil found that starting ART before 
conception increased the odds of preterm birth, although 
the effect estimate was very imprecise.25 Most recently, 
a large prospective cohort study in Tanzania found that 
HAART before conception was associated with a higher risk 
of preterm birth overall and very preterm birth in particu-
lar.29 Importantly, however, the referent population in that 
study was women starting zidovudine monotherapy after 28 
weeks of gestation, so these women (by virtue of the fact 
that their pregnancies had survived to at least 28 weeks) may 
have been at lower preterm risk than any of the groups to 
whom we compared our own women who initiated ART 
before conception. We also note that all of these prior 
studies were performed in the era when ART initiation for 
health and PMTCT was only available to those with 
advanced disease. Advanced maternal HIV is associated 
with increased preterm birth risk33 and these earlier findings 
may not be directly applicable to the Option B+ era in which 
lifelong ART is initiated during pregnancy regardless of 
HIV disease stage or CD4 count.
Findings around the relationship between preterm 
birth overall and any ART during pregnancy have been 
mixed. Preliminary results of the PROMISE trial,34 which 
randomized HIV-positive pregnant women with high CD4 
counts to one of 2 triple antiretroviral regimens versus 
antepartum zidovudine, found an association between the 
triple antiretroviral arms and birth before 37 weeks, but not 
birth before 34 weeks. However, a recent study from South 
Africa reported significantly lower odds of preterm birth 
among women receiving any ART under Option B+ versus 
those not receiving ART.35 In general, heterogeneities 
across studies, particularly with respect to ART regimens, 
analytical choices around referent populations, and inclusion 
of women starting ART after preterm risk began, make 
direct comparison between our findings and those of 
previous studies difficult.
To our knowledge, our study is the first to provide 
evidence that ART initiation before conception is protective 
against preterm birth in the era of Option B+. As the Option 
B+ program matures and the proportion of women on 
lifelong ART after a prior pregnancy grows, we expect that 
increasing proportions of women will be on ART before 
conception. Our finding that preterm risk was lowest in this 
group suggests that preterm prevalence among HIV-infected 
mothers is likely to decrease as the time since Option B+ 
implementation increases. Our results also suggest that 
being on ART during pregnancy is protective against 
extremely to very preterm birth, regardless of time of ART 
initiation. These findings suggest that increased ART uptake 
in the Option B+ era could have a profound impact on 
preterm birth and neonatal mortality in developing countries 
where fertility rates are high, HIV is endemic, and advanced 
nursery facilities are not readily available.
Several mechanisms have been hypothesized for pos-
sible adverse effects of ART on birth outcomes. Specifically, 
it has been proposed that protease inhibitor (PI)-based ART 
could induce preterm birth by a cytokine-mediated regulation 
of the immune system through increased Th1 and decreased 
Th2 cytokines production.36,37 Women with recurrent preg-
nancy losses have been observed to have increased Th1 and 
decreased Th2 cytokines.38,39 Compared with non-PI-based 
ART, women on PI-based ART have a higher risk of having 
preterm birth.20,21 However, the same cytokine mechanism 
has been hypothesized to be protective against HIV disease 
progression.40,41 Women who are on established ART before 
conception may have a stabilized cytokine environment due 
to long exposure to ART, which can be one reason we 
observed ART initiation before pregnancy being protective 
against preterm birth. In addition, the ART regimen used in 
Malawi, tenofovir/lamivudine/efavirenz, is not PI-based, 
which may explain the similar preterm birth risk we observed 
in women who initiated ART at any point before 27 weeks 
and those who never initiated ART.
Studies focusing on the association between ART 
exposure duration in utero and other fetal outcomes have 
also suggested that earlier ART is not detrimental. Earlier 
ART initiation during pregnancy was not associated with 
increased risk of stillbirth or low birthweight (LBW) in South 
Africa (with ART initiation dichotomized at ,28 weeks or
$28 weeks of pregnancy)18 or with LBW in the United States 
(with ART initiation dichotomized at #25 weeks or $32 
weeks of gestation).24 A recent cohort analysis in Zambia 
among infants born at term also did not find increased risk of 
LBW or decreased mean birthweight because of longer ART 
duration during pregnancy.42
ART duration during pregnancy is intrinsically linked 
to length of gestation and thus preterm birth. To confine the 
preterm risk period to an interval in which women were either 
always or never on ART, and to maximize the number of 
ART initiation intervals (before pregnancy, during the first 
trimester, during the second trimester) before the start of the 
risk period that we could examine, we restricted our analysis 
to births that occurred on or after 27 weeks and to women 
who either started ART before 27 weeks or did not receive 
ART at all before delivery. We are therefore unable to draw 
any conclusions about the effects of early ART on extremely 
early preterm birth (before 27 weeks) or the effects of ART 
initiated at or after 27 weeks on subsequent preterm births.
We note that there may have been some misclassifica-
tion of preterm status and ART initiation time within 
pregnancy because of inaccurate estimates of the LMP. The 
general consistency of our findings across analyses suggests 
that such misclassification may not be a large concern, and 
our specific finding that women initiating ART at any point 
during pregnancy were less likely to experience extremely to 
very preterm birth (versus term birth) may be especially 
robust, given the 5-week difference between the upper 
gestational age limit of very preterm (32 weeks) and the 
lower limit of full term (37 weeks).
Information on several covariates was either unavail-
able or insufficient. In particular, we did not have informa-
tion on the interrelated covariates of ART adherence, CD4
count, and viral load. Poor ART adherence can result in drug
resistance,43,44 lower CD4, and higher viral loads, leading to
adverse maternal and birth outcomes. In general, ART
adherence is high during pregnancy,45 and we expect that
the fixed-dose tenofovir/lamivudine/efavirenz combination
of 1 tablet per day in our study population would have
encouraged high adherence.14 Furthermore, we would
consider viral load and CD4 count to be casual intermediates
between ART and preterm birth, and thus statistical
adjustment would have been inappropriate even if viral load
and CD4 data had been available. We also note that there
may have been data entry errors, but we do not expect such
errors to have been differential according to exposure or
outcome status. It is, however, possible that some exclusions
due to missing LMP or ART initiation time resulted in
selection bias, but it is difficult to predict the magnitude and
direction of any such biases. Furthermore, we note that
some of our comparisons suffered from low precision due to
small numbers of births, particularly in the analyses of
preterm subcategories.
ART initiation in pregnancy is an indicator of access to
prenatal care and other health care services. In Malawi,
HIV-infected women not on ART are initiated on lifelong
ART during an antenatal care visit,46 in addition to receiving
treatment for anemia, malaria, and other infections as standard
prenatal care. Women who attend antenatal care are less likely
to deliver LBW infants, especially from preterm births.47,48 In
the likely event that the women who had never initiated ART
before delivery were less likely to have had access to prenatal
care, then the higher preterm birth risk among those who did
not initiate ART may not be fully attributable to lack of ART
during pregnancy. No information on dates or numbers of
antenatal visits, or of treatments received during such visits,
was available in the POC-EMRS to allow control for
antenatal care or specific components thereof.
Nevertheless, our results suggest that ART initiation
before delivery does not increase preterm birth risk, and that it
may in fact be protective against extremely to very preterm
birth. Our results further suggest that ART initiation before
conception may provide the optimal benefit. As the era of
Option B+ continues, postweaning ART retention should thus
be a priority. These findings also suggest that HIV testing of
women who wish to become pregnant, followed by ART
initiation before conception in those testing HIV-positive,
could be beneficial. If adequate uptake and retention can be
achieved, then Option B+ may not only dramatically reduce
vertical HIV transmission and improve maternal health, but
also reduce preterm birth in settings with heavy, overlapping
burdens of HIV and neonatal mortality.
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